Search results
Regeneron touts success with bispecific antibody in multiple myeloma trial
Clinical Trials Arena via Yahoo Finance· 4 hours agoThe data from the Phase I/II LINKER-MM1 (NCT03761108) study was...response or better, as determined...
Why Is Mustang Bio (MBIO) Stock Up 347% Today?
InvestorPlace· 3 hours agoMustang Bio (NASDAQ:MBIO) stock is taking off on Monday after the clinical-stage biopharmaceutical company announced positive results from a study. The...
EHA 2024: Brukinsa/Venclexta for CLL/SLL lacks control arm in SEQUOIA trial
Clinical Trials Arena via Yahoo Finance· 3 hours agoAt the 2024 Congress of the European Hematology Association (EHA 2024) on 14 June, preliminary...
Pfizer reports data from Phase II multiple myeloma treatment trial
Clinical Trials Arena via Yahoo Finance· 11 hours agoPfizer has announced findings from the Phase II MagnetisMM-3 clinical trial of ELREXFIO...
AstraZeneca reports positive data from Phase III mantle cell lymphoma trial
Clinical Trials Arena via Yahoo Finance· 9 hours agoAstraZeneca has reported positive data from the ECHO Phase III clinical trial where its Calquence...
Roche’s Columvi offers extended survival in Phase III DLBCL trial
Clinical Trials Arena via Yahoo Finance· 11 hours agoRoche has reported findings from the Phase III STARGLO clinical trial where Columvi, in combination...
Takeda’s epilepsy drug misses the mark in two Phase III trials
Clinical Trials Arena via Yahoo Finance· 4 hours agoThe SKYLINE trial was a double-blind Phase III study evaluating soticlestat plus standard of care...
CARsgen’s CAR T MM therapy shows early signs of efficacy in Phase I trial
Clinical Trials Arena via Yahoo Finance· 6 hours agoGlobalData is the parent company of the Clinical Trials Arena. MM is a form of blood cancer that...
Johnson & Johnson’s nipocalimab shows promise in Sjögren’s disease trial
Clinical Trials Arena via Yahoo Finance· 9 hours agoThis study included a Phase II dose-ranging trial for adults with moderately-to-severely active...
Baird lifts Mirum Pharmaceuticals shares target on study results By Investing.com
Investing.com· 6 hours ago(NASDAQ:MIRM) shares to $39 from the previous $34, while maintaining an Outperform rating on the...